{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epilepsy%2C+Focal+Seizures%2C+Partial+Seizures&page=2",
    "query": {
      "condition": "Epilepsy, Focal Seizures, Partial Seizures",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epilepsy%2C+Focal+Seizures%2C+Partial+Seizures&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T07:10:39.373Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03739840",
      "title": "A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Drug-Resistant Epilepsy",
        "Focal-Onset Seizures"
      ],
      "interventions": [
        {
          "name": "Padsevonil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 232,
      "start_date": "2019-03-06",
      "completion_date": "2020-09-28",
      "has_results": true,
      "last_update_posted_date": "2022-12-21",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 32,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03739840"
    },
    {
      "nct_id": "NCT03531008",
      "title": "Human Epilepsy Project 2: Resistant Focal Seizures Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epilepsy",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Nervous System Diseases",
        "Biomarkers"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Epilepsy Foundation of America",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 157,
      "start_date": "2018-05-07",
      "completion_date": "2022-09-30",
      "has_results": false,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03531008"
    },
    {
      "nct_id": "NCT06534502",
      "title": "Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Seizures",
        "Seizures, Focal",
        "Seizure, Partial Onset",
        "Seizure Disorder, Partial",
        "Seizure, Partial",
        "Epilepsies, Partial",
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Zonisamide Oral Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Azurity Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-09",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 2,
      "location_summary": "Winston-Salem, North Carolina • Memphis, Tennessee",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06534502"
    },
    {
      "nct_id": "NCT00001666",
      "title": "Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Partial Epilepsy",
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Cadwell High-Speed Magnetoelectric Stimulator",
          "type": "DEVICE"
        },
        {
          "name": "Magpro High-Speed Magnetoelectric Stimulator",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 32,
      "start_date": "1997-03",
      "completion_date": "2002-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001666"
    },
    {
      "nct_id": "NCT00552305",
      "title": "To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Partial Epilepsies"
      ],
      "interventions": [
        {
          "name": "lacosamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 370,
      "start_date": "2001-08",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2018-07-17",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00552305"
    },
    {
      "nct_id": "NCT06798896",
      "title": "RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Onset Seizures"
      ],
      "interventions": [
        {
          "name": "SPN-817",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 216,
      "start_date": "2024-12-30",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 1,
      "location_summary": "Port Charlotte, Florida",
      "locations": [
        {
          "city": "Port Charlotte",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06798896"
    },
    {
      "nct_id": "NCT04686786",
      "title": "An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Seizures"
      ],
      "interventions": [
        {
          "name": "CVL-865",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 105,
      "start_date": "2020-12-08",
      "completion_date": "2024-12-05",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 26,
      "location_summary": "Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04686786"
    },
    {
      "nct_id": "NCT05614063",
      "title": "A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Focal Onset Seizures"
      ],
      "interventions": [
        {
          "name": "XEN1101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xenon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 380,
      "start_date": "2022-11-18",
      "completion_date": "2026-02-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 56,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05614063"
    },
    {
      "nct_id": "NCT01262677",
      "title": "Once-A-Day Pregabalin For Partial Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Partial Seizures",
        "Epilepsies, Partial"
      ],
      "interventions": [
        {
          "name": "pregabalin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2011-02-17",
      "completion_date": "2012-08-01",
      "has_results": true,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 26,
      "location_summary": "Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01262677"
    },
    {
      "nct_id": "NCT07505004",
      "title": "Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Focal Epilepsy"
      ],
      "interventions": [
        {
          "name": "40 mg/day vormatrogine for 12 weeks",
          "type": "DRUG"
        },
        {
          "name": "30 mg/day vormatrogine for 12 weeks",
          "type": "DRUG"
        },
        {
          "name": "20 mg/day vormatrogine for 12 weeks",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Praxis Precision Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 300,
      "start_date": "2026-01-29",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-07-24T07:10:39.373Z",
      "location_count": 7,
      "location_summary": "Miami, Florida • Miami Lakes, Florida • Naples, Florida + 4 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Marlboro",
          "state": "New Jersey"
        },
        {
          "city": "Niagara Falls",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07505004"
    }
  ]
}